摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Methyl 2-methyl-2-[4-(4-{3-(2-methylaminoethoxy)phenyl}-3-methylphenyl)-piperidin-1-ylsulphonyl]propanoate | 312931-49-0

中文名称
——
中文别名
——
英文名称
Methyl 2-methyl-2-[4-(4-{3-(2-methylaminoethoxy)phenyl}-3-methylphenyl)-piperidin-1-ylsulphonyl]propanoate
英文别名
Methyl 2-methyl-2-[4-[3-methyl-4-[3-[2-(methylamino)ethoxy]phenyl]phenyl]piperidin-1-yl]sulfonylpropanoate
Methyl 2-methyl-2-[4-(4-{3-(2-methylaminoethoxy)phenyl}-3-methylphenyl)-piperidin-1-ylsulphonyl]propanoate化学式
CAS
312931-49-0
化学式
C26H36N2O5S
mdl
——
分子量
488.648
InChiKey
OKDJZTPEFDICOC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    34
  • 可旋转键数:
    10
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    93.3
  • 氢给体数:
    1
  • 氢受体数:
    7

反应信息

  • 作为反应物:
    描述:
    Methyl 2-methyl-2-[4-(4-{3-(2-methylaminoethoxy)phenyl}-3-methylphenyl)-piperidin-1-ylsulphonyl]propanoatesodium hydroxide 作用下, 以 甲醇 为溶剂, 生成 2-Methyl-2-[4-[3-methyl-4-[3-[2-(methylamino)ethoxy]phenyl]phenyl]piperidin-1-yl]sulfonylpropanoic acid
    参考文献:
    名称:
    A novel series of highly selective inhibitors of MMP-3
    摘要:
    The design and synthesis of a series of highly selective hydroxamate inhibitors of stromelysin-1 (MMP-3) is described. Substitution of a 4-biaryl piperidine sulfonamide core, which binds at the S1' subsite of MMP-3, was optimised to give potent inhibitors of MMP-3, with greater than 300-fold selectivity over MMP-1, MMP-2, MMP-9 and MMP-14. Compounds 26 and 27 were identified as having the best balance of pharmacology and properties required for topical drug delivery. (c) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.10.042
  • 作为产物:
    描述:
    methyl 2-((4-(2-methyl-3'-(2-(methylamino)ethoxy)-[1,1'-biphenyl]-4-yl)piperidin-1-yl)sulfonyl)acetate 、 碘甲烷potassium carbonate 作用下, 以 二甲基亚砜 为溶剂, 生成 Methyl 2-methyl-2-[4-(4-{3-(2-methylaminoethoxy)phenyl}-3-methylphenyl)-piperidin-1-ylsulphonyl]propanoate
    参考文献:
    名称:
    A novel series of highly selective inhibitors of MMP-3
    摘要:
    The design and synthesis of a series of highly selective hydroxamate inhibitors of stromelysin-1 (MMP-3) is described. Substitution of a 4-biaryl piperidine sulfonamide core, which binds at the S1' subsite of MMP-3, was optimised to give potent inhibitors of MMP-3, with greater than 300-fold selectivity over MMP-1, MMP-2, MMP-9 and MMP-14. Compounds 26 and 27 were identified as having the best balance of pharmacology and properties required for topical drug delivery. (c) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.10.042
点击查看最新优质反应信息

文献信息

  • Composition for the treatment of damaged tissue
    申请人:Pfizer Inc.
    公开号:US20030199440A1
    公开(公告)日:2003-10-23
    A pharmaceutical for use in damaged tissue, such as wound, treatment (e.g. healing) is described. The pharmaceutical comprising a composition which comprises: (a) a growth factor; and (b) an inhibitor agent; and optionally (c) a pharmaceutically acceptable carrier, diluent or excipient; wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.
    描述了一种用于受损组织,如伤口治疗(例如愈合)的药物。该药物包括包含以下成分的组合物:(a)生长因子;和(b)抑制剂;以及可选的(c)药用载体、稀释剂或赋形剂;其中抑制剂可以抑制至少一种在受损组织,如伤口环境中上调的特定不良蛋白质(例如特定蛋白酶)的作用。
  • METALLOPROTEASE INHIBITORS
    申请人:Pfizer Limited
    公开号:EP1181017B1
    公开(公告)日:2003-04-16
  • COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE
    申请人:Pfizer Limited
    公开号:EP1242120A2
    公开(公告)日:2002-09-25
  • US6511993B1
    申请人:——
    公开号:US6511993B1
    公开(公告)日:2003-01-28
  • [EN] COMPOSITION FOR THE TREATMENT OF DAMAGED TISSUE<br/>[FR] COMPOSITION POUR LE TRAITEMENT DE TISSU LESE
    申请人:PFIZER LTD
    公开号:WO2001049309A2
    公开(公告)日:2001-07-12
    A pharmaceutical for use in damaged tissue, such as wound, treatment (e.g. healing) is described. The pharmaceutical comprising a composition which comprises: (a) a growth factor; and (b) an inhibitor agent; and optionally (c) a pharmaceutically acceptable carrier, diluent or excipient; wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.
查看更多